Genentech provides support to help facilitate access to Genentech Oncology medicines for eligible patients. A list of Genentech Oncology medicines, indications, and program information is provided in the Table.
Genentech Oncology Access Solutions
The assistance provided by Genentech Oncology Access Solutions varies based on the patient’s prescribed medication and insurance status.
Genentech Oncology Co-pay Assistance Program
The copay program provides direct financial assistance to commercially insured patients to help with their copays, coinsurance, or other out-of-pocket costs. To be eligible for this program, patients must:
Be covered by commercial or private insurance
Be aged ≥18 years
Be receiving a Genentech Oncology product for an FDA-approved indication
Reside and receive treatment in the United States or US territories
Not be insured by state- or government-funded health plans, such as Medicare, Medicaid, Medigap, or TRICARE
Not be receiving assistance through the Genentech Patient Foundation or any other copay charitable organization.
Patients may pay as little as $5 for their prescribed Genentech Oncology product, with an annual benefit limit of $25,000 per product. Visit CopayAssistanceNow.com or call 855-692-6729 to learn more.
Genentech Patient Foundation
Eligible patients who meet specified criteria may qualify to receive their Genentech medication at no cost through the Genentech Patient Foundation. Patients may qualify if they:
Are uninsured or insured but without coverage for a Genentech medicine
Have a household adjusted gross income of $150,000 or less
Have insurance that covers Genentech medicines but have unaffordable out-of-pocket costs and have pursued other forms of financial assistance.
Click here to help your patient apply, or for more information.
Genentech Access Solutions staff can connect patients to independent copay assistance foundations. Drug-specific listings of foundations are available at Genentech-Access.com.
Adjuvant treatment of HER2-positive breast cancer, in combination with chemotherapy, or alone after multiple anthracycline-based therapies; treatment of HER2-positive metastatic breast cancer, either first-line or after ≥1 chemotherapies for metastatic disease
Treatment of metastatic HER2-positive breast cancer; adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease after neoadjuvant taxane and trastuzumab-based therapy
Adjuvant treatment of HER2-positive breast cancer as
part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or as part of a treatment regimen with docetaxel and carboplatin, or as a single agent following multimodality anthracycline-based therapy, based on an FDA-approved companion diagnostic for Herceptin; in combination with paclitaxel for first-line treatment of HER2-positive metastatic breast cancer, or as a single agent in patients who have received ≥1 chemotherapy regimens for metastatic disease, based on an FDA-approved companion diagnostic for Herceptin
Perjeta (pertuzumab) Indications
In combination with trastuzumab and docetaxel, treatment of HER2-positive metastatic breast cancer in patients without prior anti-HER2 therapy or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, and the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Indications
Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer; adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence; treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease